CliffBio
biologic

Inflectra

infliximab-dyyb

Loss of exclusivity—loss of exclusivity
CompanyCelltrion →See this company's full patent-cliff portfolio

Drug detail

Brand nameInflectra
Active ingredientinfliximab-dyyb
Strength100MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2016
Marketing statusRx

More from Celltrion

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.